CR20180456A - Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas - Google Patents
Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradasInfo
- Publication number
- CR20180456A CR20180456A CR20180456A CR20180456A CR20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A CR 20180456 A CR20180456 A CR 20180456A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- methods
- alphaviruses
- stabilize
- living
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 241000710929 Alphavirus Species 0.000 abstract 4
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 230000000087 stabilizing effect Effects 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316262P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/024365 WO2017172643A1 (en) | 2016-03-31 | 2017-03-27 | Compositions and methods for stabilizing alphaviruses with improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180456A true CR20180456A (es) | 2019-01-09 |
Family
ID=58537071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180456A CR20180456A (es) | 2016-03-31 | 2017-03-27 | Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10632184B2 (enExample) |
| EP (1) | EP3436063A1 (enExample) |
| JP (1) | JP2019513138A (enExample) |
| KR (1) | KR20180135912A (enExample) |
| CN (1) | CN109069614A (enExample) |
| AU (1) | AU2017241590A1 (enExample) |
| BR (1) | BR112018069035A2 (enExample) |
| CA (1) | CA3019529A1 (enExample) |
| CO (1) | CO2018010357A2 (enExample) |
| CR (1) | CR20180456A (enExample) |
| DO (1) | DOP2018000211A (enExample) |
| EC (1) | ECSP18081486A (enExample) |
| MX (1) | MX2018011837A (enExample) |
| NI (1) | NI201800096A (enExample) |
| PE (1) | PE20190149A1 (enExample) |
| PH (1) | PH12018502119A1 (enExample) |
| SG (1) | SG11201808458QA (enExample) |
| SV (1) | SV2018005747A (enExample) |
| WO (1) | WO2017172643A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087188A1 (en) | 2013-12-23 | 2016-11-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| WO2021028406A1 (en) * | 2019-08-09 | 2021-02-18 | Valneva Se | Chikungunya vaccine formulations |
| CA3149932A1 (en) * | 2019-08-09 | 2021-02-18 | Valneva Se | Single shot chikungunya virus vaccine |
| PH12022550939A1 (en) * | 2019-10-25 | 2024-02-12 | Bavarian Nordic As | Chikungunya virus-like particle vaccine and methods of using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545555A (en) | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| BRPI0716145B1 (pt) | 2006-09-01 | 2021-06-22 | Bharat Biotech International Limited | Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya |
| US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| US10137186B2 (en) | 2013-03-14 | 2018-11-27 | Takeda Vaccines, Inc. | Compositions and methods for live, attenuated alphavirus formulations |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
-
2017
- 2017-03-27 PE PE2018001924A patent/PE20190149A1/es unknown
- 2017-03-27 CA CA3019529A patent/CA3019529A1/en not_active Abandoned
- 2017-03-27 WO PCT/US2017/024365 patent/WO2017172643A1/en not_active Ceased
- 2017-03-27 EP EP17717027.1A patent/EP3436063A1/en not_active Withdrawn
- 2017-03-27 CR CR20180456A patent/CR20180456A/es unknown
- 2017-03-27 MX MX2018011837A patent/MX2018011837A/es unknown
- 2017-03-27 BR BR112018069035A patent/BR112018069035A2/pt not_active IP Right Cessation
- 2017-03-27 KR KR1020187031479A patent/KR20180135912A/ko not_active Ceased
- 2017-03-27 US US16/088,816 patent/US10632184B2/en not_active Expired - Fee Related
- 2017-03-27 SG SG11201808458QA patent/SG11201808458QA/en unknown
- 2017-03-27 AU AU2017241590A patent/AU2017241590A1/en not_active Abandoned
- 2017-03-27 JP JP2018550558A patent/JP2019513138A/ja not_active Withdrawn
- 2017-03-27 CN CN201780026126.8A patent/CN109069614A/zh active Pending
-
2018
- 2018-09-27 NI NI201800096A patent/NI201800096A/es unknown
- 2018-09-27 CO CONC2018/0010357A patent/CO2018010357A2/es unknown
- 2018-09-28 DO DO2018000211A patent/DOP2018000211A/es unknown
- 2018-09-28 SV SV2018005747A patent/SV2018005747A/es unknown
- 2018-10-01 PH PH12018502119A patent/PH12018502119A1/en unknown
- 2018-10-30 EC ECSENADI201881486A patent/ECSP18081486A/es unknown
-
2020
- 2020-04-08 US US16/843,439 patent/US20200306361A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20190149A1 (es) | 2019-01-22 |
| JP2019513138A (ja) | 2019-05-23 |
| BR112018069035A2 (pt) | 2019-01-29 |
| WO2017172643A1 (en) | 2017-10-05 |
| CO2018010357A2 (es) | 2019-05-21 |
| EP3436063A1 (en) | 2019-02-06 |
| SV2018005747A (es) | 2019-03-28 |
| NI201800096A (es) | 2019-02-01 |
| MX2018011837A (es) | 2019-02-13 |
| CA3019529A1 (en) | 2017-10-05 |
| ECSP18081486A (es) | 2019-01-31 |
| US20190111124A1 (en) | 2019-04-18 |
| DOP2018000211A (es) | 2018-12-31 |
| US10632184B2 (en) | 2020-04-28 |
| PH12018502119A1 (en) | 2019-07-15 |
| US20200306361A1 (en) | 2020-10-01 |
| CN109069614A (zh) | 2018-12-21 |
| KR20180135912A (ko) | 2018-12-21 |
| SG11201808458QA (en) | 2018-10-30 |
| AU2017241590A1 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012899A (es) | Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias | |
| CL2020000060A1 (es) | Compuestos antiproliferativos y métodos para utilizarlos. | |
| CL2017002050A1 (es) | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario | |
| CL2018000162A1 (es) | Composiciones ingeribles por abejas, procedimientos para el uso de las mismas para producir miel y miel producida de esta manera | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2018002999A (es) | Composiciones de inoculante estables y metodos para producir las mismas. | |
| PE20180267A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2015002433A1 (es) | Imidazopiridazinas sustituidas | |
| MX369281B (es) | Composiciones para el cuidado bucal y metodos para utilizar las composiciones. | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| MX378386B (es) | Composiciones antiirritantes sinérgicas de taurina y aloe. | |
| MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
| MX2018003700A (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos. | |
| CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| DOP2018000211A (es) | Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas | |
| CL2017001615A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2. | |
| MX2019000177A (es) | Formulaciones de anticuerpos. | |
| MX2019008460A (es) | Metodos para tratar esclerosis multiple usando celulas t autologas. | |
| AR095398A1 (es) | Formulaciones con oxidación reducida | |
| AR113514A1 (es) | Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales | |
| JOP20200126B1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| CL2016001350A1 (es) | Composiciones de ketoprofeno de accion prologanda. | |
| MX2019003212A (es) | Composiciones que comprenden tensioactivos especificos y altos niveles de glicerina. |